No he didn't. More capital will be needed, however it is TBC whether that will come via a CR or through revenue from a (hopefully more than 1) commercial license agreement. This is over 2 years away - no point worrying about that now. Data from the clinical trials we're running will be in by then and the market (and potential commercial partners/acquirers) will have a far better idea of what Cynata and the Cymerus manufacturing process is worth.
Ann: Cynata Receives $1.39m R&D Tax Incentive Refund, page-32
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.010(3.85%) |
Mkt cap ! $44.90M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.5¢ | 25.0¢ | $5.869K | 22.42K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29342 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 15.47pm 11/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |